Triple
T11145520
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | pertuzumab |
E263659
|
entity |
| Predicate | oftenUsedWith |
P4791
|
FINISHED |
| Object | trastuzumab |
E46088
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: trastuzumab | Statement: [pertuzumab, oftenUsedWith, trastuzumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: trastuzumab Context triple: [pertuzumab, oftenUsedWith, trastuzumab]
-
A.
Herceptin
chosen
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
B.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
C.
lapatinib
Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
-
D.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
E.
fam-trastuzumab deruxtecan
Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aa9c0ba08190bbd19c217489b755 |
completed | April 8, 2026, 7:21 p.m. |
| NER | Named-entity recognition | batch_69d7e8634d5481909b114d30a542ea3f |
completed | April 9, 2026, 5:56 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69e496c152a081909c6ad8b2a6e41927 |
completed | April 19, 2026, 8:48 a.m. |
Created at: April 8, 2026, 9:28 p.m.